Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma.
about
Clinical trial success rates of anti-obesity agents: the importance of combination therapies.Companion diagnostics at the intersection of personalized medicine and healthcare delivery.Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma.Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.The importance of predictive biomarkers in oncology drug development.
P2860
Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Biomarker use is associated wi ...... e risk in metastatic melanoma.
@en
type
label
Biomarker use is associated wi ...... e risk in metastatic melanoma.
@en
prefLabel
Biomarker use is associated wi ...... e risk in metastatic melanoma.
@en
P2093
P2860
P356
P1476
Biomarker use is associated wi ...... e risk in metastatic melanoma.
@en
P2093
D Scott Ernst
Daniel A Rubinger
Jayson L Parker
Sarah S Hollmann
Viktoria Serdetchnaia
P2860
P356
10.2217/BMM.14.80
P577
2015-01-01T00:00:00Z